Fund Holdings — Omega Fund Management, LLC

Total Portfolio Value
$123.44M
Total Bought
$39.80M
Total Sold
$1.76M
Net Transaction
+$38.04M
Filing Period:
Securities
▲▼
SharesValue ($K)
Q3 2023
▲▼
Q4 2023
▲▼
Change
▲▼
Q3 2023
▲▼
Q4 2023
▲▼
Weight (%)
▲▼
Change
▲▼
Lexeo Therapeutics(LXEO)02,157,623+2,157,623028,95523.46%+28,955
enGene Holdings Inc.
COM
01,131,175+1,131,175010,4418.46%+10,441
Nuvation Bio(NUVB)15,072,34015,072,340020,19722,75918.44%+2,562
Morphic Holding309,846309,84607,0998,9487.25%+1,850
Spruce Biosciences2,161,0222,161,02204,8846,3325.13%+1,448
Theseus Pharmaceuticals711,479711,47901,9142,8812.33%+968
Syros Pharmaceuticals251,270251,27009931,9571.59%+965
enGene Holdings Inc.
*W EXP 10/31/202
0475,077+475,07704040.33%+404
Sana Biotechnology, Inc.(SANA)843,750843,75003,2653,4432.79%+177
Immunic Inc(IMUX)1,788,1601,788,16002,6292,6822.17%+54
Senti Biosciences, Inc.195,792195,7920811290.10%+48
Kronos Bio3,818,2833,818,28304,9644,7733.87%-191
Alpine Immune Sciences153,7000-153,7001,7600—-1,760
Ikena Oncology2,249,1232,249,12309,7394,4313.59%-5,308
Replimune Group(REPL)3,001,3193,001,319051,35325,30120.50%-26,051
Page 1 of 1
Omega Fund Management, LLC — 13F Holdings — Q4 2023 | TickerTrail